FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2602359212> ?p ?o ?g. }

• W2602359212 endingPage "38500" @default.
• W2602359212 startingPage "38491" @default.
• W2602359212 abstract "// Jun Zhang 1, * , Nan Wu 1, * , Tiemei Zhang 2 , Tao Sun 3 , Yi Su 3 , Jing Zhao 1 , Kun Mu 1 , Zhao Jin 1 , Ming Gao 4 , Juntian Liu 1 , Lin Gu 1 1 Department of Breast Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China 2 Department of Endoscopy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China 3 Department of Breast Surgery, Hebei Province Cangzhou City Nanpi People’s Hospital, Cangzhou 061500, China 4 Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China * These authors contributed equally to this work Correspondence to: Ming Gao, email: headandneck15@aliyun.com Lin Gu, email: doctorgulin@163.com Juntian Liu, email: Ljt641024@163.com Keywords: breast cancer, radiotherapy, FATS, biomarker Received: November 14, 2016      Accepted: March 01, 2017      Published: March 28, 2017 ABSTRACT Purpose: The fragile-site associated tumor suppressor (FATS) is a newly identified tumor suppressor involved in radiation-induced tumorigenesis. The purpose of this study was to characterize FATS expression in breast cancers about radiotherapy benefit, patient characteristics, and prognosis. Results: The expression of FATS mRNA was silent or downregulated in 95.2% of breast cancer samples compared with paired normal controls ( P < .0001). Negative status of FATS was correlated with higher nuclear grade ( P = .01) and shorter disease-free survival (DFS) of breast cancer ( P = .036). In a multivariate analysis, FATS expression showed favorable prognostic value for DFS (odds ratio, 0.532; 95% confidence interval, 0.299 to 0.947; ( P = .032). Furthermore, improved survival time was seen in FATS-positive patients receiving radiotherapy ( P = .006). The results of multivariate analysis revealed independent prognostic value of FATS expression in predicting longer DFS (odds ratio, 0.377; 95% confidence interval, 0.176 to 0.809; P = 0.012) for patients receiving adjuvant radiotherapy. In support of this, reduction of FATS expression in breast cancer cell lines, FATS positive group significantly sensitized than Knock-down of FATS group. Materials and Methods: Tissue samples from 156 breast cancer patients and 42 controls in tumor bank were studied. FATS gene expression was evaluated using quantitative reverse transcription polymerase chain reaction (qRT-PCR). FATS function was examined in breast cancer cell lines using siRNA knock-downs and colony forming assays after irradiation. Conclusions: FATS status is a biomarker in breast cancer to identify individuals likely to benefit from radiotherapy." @default.
• W2602359212 created "2017-04-07" @default.
• W2602359212 creator A5007433995 @default.
• W2602359212 creator A5012971057 @default.
• W2602359212 creator A5027205195 @default.
• W2602359212 creator A5047993178 @default.
• W2602359212 creator A5056435425 @default.
• W2602359212 creator A5059791084 @default.
• W2602359212 creator A5061543595 @default.
• W2602359212 creator A5064008354 @default.
• W2602359212 creator A5072667148 @default.
• W2602359212 creator A5074908633 @default.
• W2602359212 creator A5083953677 @default.
• W2602359212 date "2017-03-28" @default.
• W2602359212 modified "2023-10-16" @default.
• W2602359212 title "The value of FATS expression in predicting sensitivity to radiotherapy in breast cancer" @default.
• W2602359212 cites W1924240366 @default.
• W2602359212 cites W1948838904 @default.
• W2602359212 cites W1965734230 @default.
• W2602359212 cites W1967043475 @default.
• W2602359212 cites W1978627461 @default.
• W2602359212 cites W1998323202 @default.
• W2602359212 cites W2009711853 @default.
• W2602359212 cites W2013402070 @default.
• W2602359212 cites W2023719828 @default.
• W2602359212 cites W2036755756 @default.
• W2602359212 cites W2042209799 @default.
• W2602359212 cites W2043915060 @default.
• W2602359212 cites W2044702943 @default.
• W2602359212 cites W2077990465 @default.
• W2602359212 cites W2099356722 @default.
• W2602359212 cites W2118126404 @default.
• W2602359212 cites W2121906079 @default.
• W2602359212 cites W2122761438 @default.
• W2602359212 cites W2132178722 @default.
• W2602359212 cites W2157276711 @default.
• W2602359212 cites W2159012899 @default.
• W2602359212 cites W2163837533 @default.
• W2602359212 cites W2171486016 @default.
• W2602359212 cites W2223071669 @default.
• W2602359212 cites W2397479463 @default.
• W2602359212 cites W2414745107 @default.
• W2602359212 cites W2469615413 @default.
• W2602359212 cites W3143166964 @default.
• W2602359212 doi "https://doi.org/10.18632/oncotarget.16630" @default.
• W2602359212 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5503548" @default.
• W2602359212 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28402275" @default.
• W2602359212 hasPublicationYear "2017" @default.
• W2602359212 type Work @default.
• W2602359212 sameAs 2602359212 @default.
• W2602359212 citedByCount "2" @default.
• W2602359212 countsByYear W26023592122021 @default.
• W2602359212 countsByYear W26023592122023 @default.
• W2602359212 crossrefType "journal-article" @default.
• W2602359212 hasAuthorship W2602359212A5007433995 @default.
• W2602359212 hasAuthorship W2602359212A5012971057 @default.
• W2602359212 hasAuthorship W2602359212A5027205195 @default.
• W2602359212 hasAuthorship W2602359212A5047993178 @default.
• W2602359212 hasAuthorship W2602359212A5056435425 @default.
• W2602359212 hasAuthorship W2602359212A5059791084 @default.
• W2602359212 hasAuthorship W2602359212A5061543595 @default.
• W2602359212 hasAuthorship W2602359212A5064008354 @default.
• W2602359212 hasAuthorship W2602359212A5072667148 @default.
• W2602359212 hasAuthorship W2602359212A5074908633 @default.
• W2602359212 hasAuthorship W2602359212A5083953677 @default.
• W2602359212 hasBestOaLocation W26023592121 @default.
• W2602359212 hasConcept C121608353 @default.
• W2602359212 hasConcept C126322002 @default.
• W2602359212 hasConcept C143998085 @default.
• W2602359212 hasConcept C509974204 @default.
• W2602359212 hasConcept C530470458 @default.
• W2602359212 hasConcept C71924100 @default.
• W2602359212 hasConceptScore W2602359212C121608353 @default.
• W2602359212 hasConceptScore W2602359212C126322002 @default.
• W2602359212 hasConceptScore W2602359212C143998085 @default.
• W2602359212 hasConceptScore W2602359212C509974204 @default.
• W2602359212 hasConceptScore W2602359212C530470458 @default.
• W2602359212 hasConceptScore W2602359212C71924100 @default.
• W2602359212 hasIssue "24" @default.
• W2602359212 hasLocation W26023592121 @default.
• W2602359212 hasLocation W26023592122 @default.
• W2602359212 hasLocation W26023592123 @default.
• W2602359212 hasLocation W26023592124 @default.
• W2602359212 hasOpenAccess W2602359212 @default.
• W2602359212 hasPrimaryLocation W26023592121 @default.
• W2602359212 hasRelatedWork W2060905781 @default.
• W2602359212 hasRelatedWork W2155962753 @default.
• W2602359212 hasRelatedWork W2224319365 @default.
• W2602359212 hasRelatedWork W2384708512 @default.
• W2602359212 hasRelatedWork W2466949046 @default.
• W2602359212 hasRelatedWork W2972384824 @default.
• W2602359212 hasRelatedWork W3029766897 @default.
• W2602359212 hasRelatedWork W3030082946 @default.
• W2602359212 hasRelatedWork W3101879963 @default.
• W2602359212 hasRelatedWork W4226117390 @default.
• W2602359212 hasVolume "8" @default.
• W2602359212 isParatext "false" @default.
• W2602359212 isRetracted "false" @default.

• next